Editorial: Quality of Life in Breast Cancer Patients and Survivors

Invernizzi, Marco; Kim, Ji Sun; Fusco, Nicola

doi:10.3389/fonc.2020.620574

Cited by 38 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with breast cancer metastatic to the bone require a multidisciplinary approach that should consider not only the clinical scenario but also the tumor specific biology [9,18,[67][68][69][70][71][72]. Indeed, the metastatic process involves several pathways that are intimately related to breast cancer biomarkers, such as estrogen receptor, progesterone receptor, and HER2 [73].…”

Section: Bone-targeting Therapies For Breast Cancer Patients With Bonmentioning

confidence: 99%

“…Bone metastases not only considerably reduce the OS but also the health-related quality of life due to pain, fatigue, and skeletal-related events (SREs) [8][9][10]. Several therapeutic strategies to specifically target this condition (e.g., bone-modifying agents) are currently available [9,[11][12][13]. However, their reliability and impact on patients' frailty remain a subject of debate [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Venetis

Piciotti

Sajjadi

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

Despite the remarkable advances in the diagnosis and treatment of breast cancer patients, the presence or development of metastasis remains an incurable condition. Bone is one of the most frequent sites of distant dissemination and negatively impacts on patient’s survival and overall frailty. The interplay between tumor cells and the bone microenvironment induces bone destruction and tumor progression. To date, the clinical management of bone metastatic breast cancer encompasses anti-tumor systemic therapies along with bone-targeting agents, aimed at slowing bone resorption to reduce the risk of skeletal-related events. However, their effect on patients’ survival remains controversial. Unraveling the biology that governs the interplay between breast neoplastic cells and bone tissue would provide means for the development of new therapeutic agents. This article outlines the state-of-the art in the characterization and targeting the bone metastasis in breast cancer, focusing on the major clinical and translational studies on this clinically relevant topic.

show abstract

Section: Bone-targeting Therapies For Breast Cancer Patients With Bonmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Venetis

Piciotti

Sajjadi

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite advancements in the treatment of these patients, metastatic breast cancer (MBC) substantially remains an incurable disease ( 2 ). Difficulties related to the clinical management of these patients include prolongation of overall survival (OS), control of increasingly severe symptoms, and preservation of the health-related quality of life ( 3 , 4 ). The currently available therapeutic options for MBC are chemotherapy, endocrine therapy (ET), targeted therapies, and immunotherapy ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Despite the significant achievements in the diagnosis and treatment of metastatic breast cancer (MBC), this condition remains substantially an incurable disease. In recent years, several clinical studies have aimed to identify novel molecular targets, therapeutic strategies, and predictive biomarkers to improve the outcome of women with MBC. Overall, ~40% of hormone receptor (HR)+/HER2− MBC cases harbor alterations affecting the (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. This pathway is a major target in oncogenesis, as it regulates growth, proliferation, cell survival, and angiogenesis. Lately, the pharmacologic targeting of PIK3CA in HR+/HER2− MBC has shown significant benefits after the occurrence of endocrine therapy resistance. The orally available α-selective PIK3CA inhibitor, alpelisib, has been approved in this setting. To perform an optimal patients' selection for this drug, it is crucial to adopt a tailored methodology. Clinically relevant PIK3CA alterations may be detected in several biospecimens (e.g. tissue samples and liquid biopsy) using different techniques (e.g. real-time PCR and next-generation sequencing). In this study, we provide an overview of the role of PIK3CA in breast cancer and of the characterization of its mutational status for appropriate clinical management.

show abstract

“…Impairment of cognitive function and affective function after diagnosis of breast cancer were reported (5), and alteration of hippocampus like deformation or volume loss were also found after major types of treatments. Some pivotal studies aimed at the survivorship of returning the quality of life to the status before diagnosis or even better (6). Breast cancer experience could have an impact on physical and psychosocial alterations such as increased risk of depression, anxiety, and intrusive thought, especially in younger patients.…”

Section: Introductionmentioning

confidence: 99%

Association of Insomnia, Depressive Disorders, and Mood Disorders as Risk Factors With Breast Cancer: A Nationwide Population-Based Cohort Study of 232,108 Women in Taiwan

et al. 2021

View full text Add to dashboard Cite

BackgroundInsomnia, depressive disorders, and to a more general view, mood disorders are raising people’s concerns and causing disability of life. Herein, we try to seek the association of such illnesses with subsequent breast cancer.MethodsThis population-based, retrospective cohort study used data from the Taiwan National Health Insurance Research Database. This study included 232,108 women diagnosed with insomnia, depressive disorders, and mood disorders from January 1, 2000 to December 31, 2013. Physician diagnosed insomnia, depressive disorders, or mood disorders using outpatient and inpatient records before diagnosis of breast cancer. Cox proportional hazards regression analysis is adjusted for women with insomnia, depressive disorders, mood disorders, and other factors like insured amount, urbanization, and comorbidities such as having subsequent breast cancer.ResultsSleep medication was associated with a significantly increased incidence rate of breast cancer (aHR = 1.23 (95% CI = 1.13, 1.35), p < 0.001). Insomnia was associated with significant increased hazard of breast cancer (aHR = 1.16 (95% CI = 1.07, 1.27), p < 0.001). Annual insured amount >20,000 (TWD), high urbanization area, and hyperlipidemia were associated with increased hazard of breast cancer (aHR = 1.13 (95% CI = 1.01, 1.27), p = 0.04; aHR = 1.41 (95% CI = 1.17, 1.71), p < 0.001; aHR = 1.14 995% CI = 1.02, 1.29), p = 0.02, respectively). There was a positive correlation between depressive disorders and increased incidence rate of breast cancer but not statistically significant (aHR = 1.11 (95% CI = 0.99, 1.25), p = 0.08). Mood disorders were not associated with increased hazard (aHR = 1.11 (95% CI = 0.91, 1.34), p = 0.31).ConclusionIn this study, women with insomnia had increased risk of breast cancer, particularly those in high urbanization or with high insured amounts. Sleep medication (benzodiazepine (BZD) or non-BZD) and hyperlipidemia were independently associated with a higher hazard ratio of breast cancer. Insomnia along with sleep medication did not yield more hazards than each alone. Mood disorders appeared to be not associated with subsequent breast cancer. However, depressive disorders, the subgroups of mood disorders, could possibly increase the incidence rate of breast cancer though not statistically significant.

show abstract

Editorial: Quality of Life in Breast Cancer Patients and Survivors

Cited by 38 publications

References 16 publications

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Association of Insomnia, Depressive Disorders, and Mood Disorders as Risk Factors With Breast Cancer: A Nationwide Population-Based Cohort Study of 232,108 Women in Taiwan

Contact Info

Product

Resources

About